Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee Sells 2,237 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 2,237 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $8.02, for a total transaction of $17,940.74. Following the completion of the transaction, the chief executive officer now owns 489,697 shares of the company’s stock, valued at $3,927,369.94. This represents a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $6.89 on Friday. Bicycle Therapeutics plc has a fifty-two week low of $6.77 and a fifty-two week high of $28.67. The firm has a market capitalization of $476.80 million, a PE ratio of -2.09 and a beta of 1.40. The stock’s 50-day simple moving average is $10.77 and its 200-day simple moving average is $16.93.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. During the same quarter in the prior year, the company earned ($1.16) EPS. Bicycle Therapeutics’s quarterly revenue was down 30.2% on a year-over-year basis. Sell-side analysts forecast that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BCYC. The Manufacturers Life Insurance Company grew its position in Bicycle Therapeutics by 33.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock worth $2,935,000 after purchasing an additional 32,313 shares during the period. FMR LLC purchased a new stake in shares of Bicycle Therapeutics in the third quarter worth about $3,406,000. Erste Asset Management GmbH acquired a new stake in Bicycle Therapeutics during the third quarter worth about $325,000. Point72 Asset Management L.P. raised its position in Bicycle Therapeutics by 1,438.1% during the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock valued at $20,362,000 after acquiring an additional 841,299 shares in the last quarter. Finally, State Street Corp lifted its holdings in Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after acquiring an additional 60,399 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. JMP Securities decreased their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Stephens restated an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.14.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.